Type 3 muscarinic receptors contribute to clearance of Citrobacter rodentium

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1860-1871

  McLean, Leon P ^a   Smith, Allen ^b   Cheung, Lumei ^b   Sun, Rex ^a   Grinchuk, Viktoriya ^a   Vanuytsel, Tim ^c   Desai, Neemesh ^a   Urban, Joseph F ^b   Zhao, Aiping ^a   Raufman, Jean Pierre ^a   Shea Donohue, Terez ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Citrobacter rodentium; Colitis; Mucus; Muscarinic receptor; TH1 TH17 immunity

Indexed keywords

ATROPINE; BETHANECHOL; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; MUCIN 2; MUSCARINIC M3 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; MUCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL TRANSLOCATION; BACTERIUM ADHERENCE; BONE MARROW DERIVED MACROPHAGE; CELL COUNT; CELL STIMULATION; CITROBACTER RODENTIUM; CITROBACTER RODENTIUM INFECTION; COLON MUCOSA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RESPONSE; ENTEROBACTERIACEAE INFECTION; GENE EXPRESSION; GOBLET CELL; HISTOPATHOLOGY; HOMEOSTASIS; HOST RESISTANCE; IMMUNE RESPONSE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN SIZE; TH1 CELL; TH17 CELL; UPREGULATION; ANIMAL; CELL PROLIFERATION; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; MALE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CELL PROLIFERATION; CITROBACTER RODENTIUM; CYTOKINES; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GOBLET CELLS; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MUCINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, MUSCARINIC M3;

EID: 84938734785     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000408     Document Type: Article

References (55)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54 e42; quiz e30.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 2005;206:296-305.
4. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev. 2005;206:277-295.
5. Higgins LM, Frankel G, Douce G, et al. Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun. 1999;67:3031-3039.
6. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14:282-289.
7. Symonds EL, Riedel CU, O'Mahony D, et al. Involvement of T helper type 17 and regulatory T cell activity in Citrobacter rodentium invasion and inflammatory damage. Clin Exp Immunol. 2009;157:148-154.
8. Alipour M, Lou Y, Zimmerman D, et al. A balanced IL-1beta activity is required for host response to Citrobacter rodentium infection. PLoS One. 2013;8:e80656.
9. Maaser C, Housley MP, Iimura M, et al. Clearance of Citrobacter rodentium requires B cells but not secretory immunoglobulin A (IgA) or IgM antibodies. Infect Immun. 2004;72:3315-3324.
10. Vallance BA, Deng W, Knodler LA, et al. Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection. Infect Immun. 2002;70:2070-2081.
11. Round AN, Rigby NM, Garcia de la Torre A, et al. Lamellar structures of MUC2-rich mucin: a potential role in governing the barrier and lubricating functions of intestinal mucus. Biomacromolecules. 2012;13:3253-3261.
12. Bergstrom KS, Kissoon-Singh V, Gibson DL, et al. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog. 2010;6:e1000902.
13. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4659-4665.
14. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809.
15. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458-462.
16. Dhawan S, Cailotto C, Harthoorn LF, et al. Cholinergic signalling in gut immunity. Life Sci. 2012;91:1038-1042.
17. Pieper MP. The non-neuronal cholinergic system as novel drug target in the airways. Life Sci. 2012;91:1113-1118.
18. Lundgren O, Jodal M, Jansson M, et al. Intestinal epithelial stem/progenitor cells are controlled by mucosal afferent nerves. PLoS One. 2011;6:e16295.
19. Kojima Y, Ishihara K, Komuro Y, et al. Effects of the muscarinic receptor agonist carbachol and/or antagonist pirenzepine on gastric mucus secretion in rats. Scand J Gastroenterol. 1993;28:647-651.
20. Specian RD, Neutra MR. Mechanism of rapid mucus secretion in goblet cells stimulated by acetylcholine. J Cell Biol. 1980;85:626-640.
21. Cao R, Dong XW, Jiang JX, et al. M(3) muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice. Eur J Pharmacol. 2011;655:83-90.
22. Kistemaker LE, Bos IS, Hylkema MN, et al. Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice. Eur Respir J. 2013;42:1677-1688.
23. Kawashima K, Fujii T, Moriwaki Y, et al. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. Life Sci. 2012;91:1027-1032.
24. El Asmar R, Panigrahi P, Bamford P, et al. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology. 2002;123:1607-1615.
25. Shen-Tu G, Schauer DB, Jones NL, et al. Detergent-resistant microdomains mediate activation of host cell signaling in response to attaching-effacing bacteria. Lab Invest. 2010;90:266-281.
26. Yang Z, Grinchuk V, Ip SP, et al. Anti-inflammatory activities of a Chinese herbal formula IBS-20 in vitro and in vivo. Evid Based Complement Alternat Med. 2012;2012:491496.
27. Wang F, Schwarz BT, Graham WV, et al. IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology. 2006;131:1153-1163.
28. Youakim A, Ahdieh M. Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am J Physiol. 1999;276:G1279-G1288.
29. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
30. Su L, Nalle SC, Shen L, et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology. 2013;145:407-415.
31. Madden KB, Whitman L, Sullivan C, et al. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. J Immunol. 2002;169:4417-4422.
32. Madden KB, Yeung KA, Zhao A, et al. Enteric nematodes induce stereotypic STAT6-dependent alterations in intestinal epithelial cell function. J Immunol. 2004;172:5616-5621.
33. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2:416-422.
34. Brown JB, Cheresh P, Goretsky T, et al. Epithelial phosphatidylinositol-3-kinase signaling is required for beta-catenin activation and host defense against Citrobacter rodentium infection. Infect Immun. 2011;79:1863-1872.
35. Hasnain SZ, Wang H, Ghia JE, et al. Mucin gene deficiency in mice impairs host resistance to an enteric parasitic infection. Gastroenterology. 2010;138:1763-1771.
36. Li W, Yan F, Zhou H, et al. P. aeruginosa lipopolysaccharide-induced MUC5AC and CLCA3 expression is partly through Duox1 in vitro and in vivo. PLoS One. 2013;8:e63945.
37. Tytgat KM, Buller HA, Opdam FJ, et al. Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucin. Gastroenterology. 1994;107:1352-1363.
38. Atuma C, Strugala V, Allen A, et al. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 2001;280:G922-G929.
39. Hasnain SZ, Evans CM, Roy M, et al. Muc5ac: a critical component mediating the rejection of enteric nematodes. J Exp Med. 2011;208:893-900.
40. Cailotto C, Gomez-Pinilla PJ, Costes LM, et al. Neuro-anatomical evidence indicating indirect modulation of macrophages by vagal efferents in the intestine but not in the spleen. PLoS One. 2014;9:e87785.
41. Matteoli G, Gomez-Pinilla PJ, Nemethova A, et al. A distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen. Gut. 2014;63:938-948.
42. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol. 2005;6:844-851.
43. Lorsbach RB, Murphy WJ, Lowenstein CJ, et al. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide. J Biol Chem. 1993;268:1908-1913.
44. Deplancke B, Gaskins HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr. 2001;73:1131S-1141S.
45. Wlodarska M, Willing B, Keeney KM, et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect Immun. 2011;79:1536-1545.
46. Klapproth JM, Sasaki M, Sherman M, et al. Citrobacter rodentium lifA/efa1 is essential for colonic colonization and crypt cell hyperplasia in vivo. Infect Immun. 2005;73:1441-1451.
47. Qi W, Weber CR, Wasland K, et al. Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. Am J Physiol Gastrointest Liver Physiol. 2011;300:G264-G272.
48. Chan JM, Bhinder G, Sham HP, et al. CD4+ T cells drive goblet cell depletion during Citrobacter rodentium infection. Infect Immun. 2013;81:4649-4658.
49. Gill N, Wlodarska M, Finlay BB. Roadblocks in the gut: barriers to enteric infection. Cell Microbiol. 2011;13:660-669.
50. Szentkuti L, Riedesel H, Enss ML, et al. Pre-epithelial mucus layer in the colon of conventional and germ-free rats. Histochem J. 1990;22:491-497.
51. Koarai A, Traves SL, Fenwick PS, et al. Expression of muscarinic receptors by human macrophages. Eur Respir J. 2012;39:698-704.
52. Razani-Boroujerdi S, Behl M, Hahn FF, et al. Role of muscarinic receptors in the regulation of immune and inflammatory responses. J Neuroimmunol. 2008;194:83-88.
53. The FO, Boeckxstaens GE, Snoek SA, et al. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology. 2007;133:1219-1228.
54. Snoek SA, Verstege MI, van der Zanden EP, et al. Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br J Pharmacol. 2010;160:322-333.
55. Koopman FA, Schuurman PR, Vervoordeldonk MJ, et al. Vagus nerve stimulation: a new bioelectronics approach to treat rheumatoid arthritis? Best Pract Res Clin Rheumatol. 2014;28:625-635.